Journal article
Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence update.
Abstract
BACKGROUND: One-year mortality outcomes in the PARTNER trial showed that transcatheter aortic valve implantation (TAVI) was noninferior to surgical aortic valve replacement (sAVR) in patients who were eligible for sAVR (cohort A), and superior to standard treatment in patients who were ineligible for sAVR (cohort B).
OBJECTIVE: To update a previous report on the safety, effectiveness, and cost-effectiveness of TAVI, published in 2012.
Authors
Sehatzadeh S; Doble B; Xie F; Blackhouse G; Campbell K; Kaulback K; Chandra K; Goeree R
Journal
Ontario health technology assessment series, Vol. 13, No. 1, pp. 1–40
Publication Date
2013
ISSN
1915-7398